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http://dx.doi.org/10.1016/j.ajpath.2014.01.023In acute kidney injury, which is a signiﬁcant cause of morbidity and mortality, cytokines and leukocytes
promote inﬂammation and injury. We examined the pathogenic role of IL-17A in cisplatin-induced acute
kidney injury. Intrarenal IL-17A mRNA transcription and protein expression were increased in wild-type
mice after cisplatin-induced renal injury. An important role for IL-17A in the nephrotoxicity of cisplatin
was demonstrated by observing protection from cisplatin-induced functional and histological renal injury
in Il17a/ and Rorgt/mice, as well as inmice treated pre-emptively with antieIL-17A antibodies. Both
renal injury and renal IL-1b and IL-17Aproductionwere attenuated inAsc/ and Tlr2/mice, suggesting
that cisplatin induces endogenous TLR2 ligand production and activates the ASC-dependent inﬂamma-
some complex, resulting in IL-1b and injurious IL-17A production. Neutrophils and natural killer cells are
the likely targets of these pathways, because combined depletion of these cells was strongly protective;
antieIL-17A antibodies had no additional effect in this setting. Although IL-17A can also be produced by
CD4þ and gd T cells, IL-17A from those cells does not contribute to renal injury. Cisplatin-induced injury
was unchanged in gd T-celledeﬁcient mice, whereas Il17a/ CD4þ T cells induced similar injury as did
wild-type CD4þ T cells on transfer to cisplatin-injected Rag1/ mice. These studies demonstrate an
important role for TLR2, the ASC inﬂammasome, and IL-17A in innate leukocytes in cisplatin-induced renal
injury. (Am J Pathol 2014, 184: 1411e1418; http://dx.doi.org/10.1016/j.ajpath.2014.01.023)Supported in part by a Jacquot Research Establishment award (S.A.S.)
administered by the Royal Australasian College of Physicians.
A.J.C. and M.A.A. contributed equally to this work.
S.A.S. is deceased.
Disclosures: None declared.Cisplatin is an effective chemotherapeutic agent that is
commonly used in treatment of many solid organ malignancies.
The development of dose-dependent response to the nephro-
toxicity of cisplatin occurs in up to 30%of patients and is amajor
limitation to optimal dosing regimes.1 In addition to direct
tubular injury, increasing evidence supports a role for in-
ﬂammation in pathogenesis due to cisplatin nephrotoxicity.2
Administration of cisplatin to mice reliably results in inﬂam-
matory acute kidney injury (AKI), mimicking many of the fea-
tures seen in human AKI. Injury is enhanced by the production
of proinﬂammatory cytokines and leukocytes, whereas regula-
tory cells and immunomodulatory cytokines attenuate injury.2e4
The proinﬂammatory cytokine IL-17A is important in
organ inﬂammation and autoimmunity. Pathogenic roles for
IL-17A have also been well described in human autoimmunestigative Pathology.
.diseases involving the kidney and in experimental models of
renal disease.5,6 Monoclonal antibodies targeting IL-17A are
being incorporated into clinical practice for the treatment of
rheumatological and dermatological diseases.7 With appro-
priate supporting experimental data, therapeutic inhibition of
IL-17A could be used to treat or prevent human AKI.
Recently, it has been shown that activation of innate
pattern recognition receptors, including Toll-like receptors
(TLRs) and the inﬂammasome, is required for generation of
Chan et alIL-17A. Binding of surface-expressed TLRs, including
TLR2, results in expression of proeIL-1b. Subsequent acti-
vation of the inﬂammasome, an intracellular multiprotein
complex that contains a nucleotide-binding oligomerization
domain, leucine-rich repeat and pyrin, domain like receptor
(NLRP), and an adaptor protein called apoptosis-associated
speck-like protein containing a caspase recruitment domain
(ASC), results in the generation of mature IL-1b. Although
this pathway leads to the production of IL-17A in models of
infectious diseases,8,9 its relevance in autoimmunity and
kidney disease is not known. Interestingly, many of the
leukocytes that promote AKI can produce IL-17A.5 CD4þ
T cells mediate cisplatin-induced AKI,10,11 but a role for
Th17 cells has not been deﬁned. Although pathogenic roles
for neutrophil-derived IL-17A,12 gd T cells,13 and natural
killer (NK1.1) cells14 have been suggested in ischemic AKI,
their role in cisplatin-induced AKI is less well deﬁned.
In the present studies, we explored the role of IL-17A in
cisplatin-induced AKI. We found that both functional and
histological renal injury were dependent on IL-17A and were
attenuated by depletion IL-17A. Activation of the innate
pattern recognition receptor TLR2 and the ASC inﬂamma-
some was required for the production of IL-17A in the kidney
and subsequent renal injury. We also demonstrated that,
rather than IL-17A produced by CD4þ T cells, innate cells
were the effector cells mediating cisplatin-induced AKI.
Materials and Methods
Experiment Design and Ethics
Male mice (8 to 10 weeks old) were used in experiments.
C57BL/6 wild-type (WT) mice were purchased from Monash
UniversityAnimal Services (Melbourne, Australia). Il17a/,15
Rorgt/,16 Tlr2/,17 Asc/, and Tcrd/ mice from the
Jackson Laboratory (Bar Harbor, ME) were all bred at the
Monash Medical Centre Animal Facility (Clayton, VIC,
Australia). Recombinant activation geneedeﬁcient (Rag1/)
mice were bred at the Walter and Eliza Hall Institute (Mel-
bourne, Australia). Cisplatin (15 mg/kg) (Sigma-Aldrich, St.
Louis,MO)was injected intraperitoneally. Experiments ended
at either 24 or 96 hours. Neutralizing or depleting monoclonal
antibodies against IL-17A, neutrophils (anti-Ly6G), and
NK1.1 cells (anti-NK1.1) and isotype control antibodies were
purchased from Bio X Cell (West Lebanon, NH). Antibodies
(100 mg) were dissolved in 200 mL saline and injected intra-
peritoneally before cisplatin administration (day 1) and
again at 24 hours (day 1) and 72 hours (day 3) after cisplatin-
induced injury.
Studies adhered to theNationalHealth andMedicalResearch
Council of Australia guidelines for animal experimentation.
Assessment of Renal Injury
Kidney sections were ﬁxed in buffered formalin for 24
hours and embedded in parafﬁn wax. Tubular injury was1412assessed on PAS-stained sections, coded so that the person
scoring slides was masked to the group from which the
sections originated. Scoring was performed as described
previously.18e20 Tubular injury was determined by assess-
ing tubular epithelial cell loss, tubular necrosis, accumula-
tion of cellular debris, and tubular cast formation. Injury was
scored according to the percentage of affected tubules, as
viewed under high-power microscopy, on a ﬁve-point scale:
0, normal; 1, 10% to 25%; 2, 26% to 50%; 3, 51% to 75%;
and 4, 76%. Blood urea nitrogen (BUN) was measured by
autoanalyzer on serum collected at the end of experiments.
Interstitial CD4þ and Neutrophil Staining
Kidney sections were ﬁxed in periodateelysineeparafor-
maldehyde for 4 hours, washed with 20% sucrose solution,
and frozen in liquid nitrogen. A three-layered immunoper-
oxidase technique as described previously21,22 was used to
stain for T cells and neutrophils on 6-mm tissue sections.
The primary antibodies used were GK1.5 (anti-mouse CD4;
ATCC, Manassas, VA) and RB6e8C5 (antieGr-1; DNAX,
Palo Alto, CA) for neutrophils. The secondary antibody
used was rabbit anti-rat biotin (BD Biosciences, San Jose,
CA; North Ryde, Australia). A minimum of 20 consecutive
interstitial ﬁelds were assessed per animal, and results were
expressed as cells per high-power ﬁeld.
Intrarenal Cytokine mRNA Expression and Intrarenal
IL-17A and IL-1b Protein
To assess mRNA expression of IL-17A, CCL5, CCL2,
CXCL1, CXCL2, and CCL20, RNA was extracted from
whole kidney as described previously and was measured
by quantitative real-time PCR.21,22 Gene-speciﬁc oligonu-
cleotides were synthesized (Life Technologies, Carlsbad,
CA; Melbourne, Australia) as described previously.21,22
Expression was standardized to 18S (housekeeping gene)
before being expressed as a fold change relative to control
or cisplatin-injected mice. To measure IL-17A and IL-1b
protein, kidneys were placed in 5% fetal calf serum and
homogenized. Homogenates were centrifuged at 167,700  g
for 15 minutes. Supernatants were isolated and assessed for
cytokine production of IL-17A (R&D Systems, Minneapolis,
MN) and IL-1b (Elisa Kit, Victoria, Australia).
Leukocyte Isolation and Flow Cytometry
Kidneys were ﬁnely minced, then digested with 5 mg/mL
collagenase D (Roche Diagnostics, Indianapolis, IN) and
100 mg/mL DNase I (Roche Diagnostics) in Hanks’
balanced salt solution (37C, 20 minutes) (Sigma-Aldrich).
Kidney cells were dissociated with a 1000-mL pipette tip
and incubated for 5 minutes. This step was repeated before
cells were gently passed through a 20-gauge syringe until
smooth and washed in PBS (with 0.5% bovine serum
albumin, 2 mmol/L EDTA). Cells were ﬁltered using a 40-mmajp.amjpathol.org - The American Journal of Pathology
Figure 1 Kidney IL-17A mRNA expression increases after cisplatin
administration in WT mice. A: Relative to unadministered mice, kidney IL-
17A expression was increased at 24 hours after cisplatin injections, but
returned to baseline by 96 hours. B: Expression of the key Th17-attracting
chemokine CCL20 peaked at 96 hours. C and D: Kidney expression of two
key neutrophil chemoattractants, CXCL1 (C) and CXCL2 (D), peaked at 24
and 96 hours after cisplatin administration, respectively. Data are
expressed as means  SEM. n Z 8 (untreated; treated, 96 hours).
*P < 0.05, **P < 0.01, and ***P < 0.001.
Figure 2 Functional and histological renal injury decreases in the
absence of IL-17A. A and B: At 96 hours after cisplatin administration,
functional renal injury measured by serum BUN (A) and histological injury
score (B) was decreased in Il17a/ mice, relative to WT mice. CeF:
Representative low- and high-power photomicrographs of tubulointerstitial
injury in WT (C and E) and Il17a/ (D and F) mice. Data are expressed as
means  SEM. n Z 8 (Il17a/) or 9 (WT). **P < 0.01; ***P < 0.001.
IL-17A Directs Acute Kidney Injurycell strainer (BD Biosciences), erythrocytes were lysed,
and the CD45þ leukocyte population was isolated using
magnetic-activated cell sorting with mouse CD45 MicroBeads
(Miltenyi Biotec, Auburn, CA; Bergisch Gladbach, Germany).
For IL-17A intracellular cytokine staining, CD45þ renal cells
were activated by incubation with 50 ng/mL phorbol 12-
myristate 13-acetate (PMA; Sigma-Aldrich) and 1 mg/mL ion-
omycin (Sigma-Aldrich) in X-VIVO 20 medium (37C,
4 hours) (Lonza, Walkersville, MD). After 30 minutes, 10 mg/
mL brefeldin A (Sigma-Aldrich) was added. Cells were washed
and stained for 20minutes at 4Cwithﬂuorochrome-conjugated
antibodies: anti-mouse CD45 (Paciﬁc Blue, 30-F11; Bio-
Legend, San Diego, CA), anti-mouse CD4 (phycoerythrin,
GK1.5; eBioscience, San Diego, CA), and anti-mouse Ly6G
(APC, 1A8; BD Biosciences). Intracellular IL-17A staining
(ﬂuorescein isothiocyanate, eBio17B7; eBioscience) was per-
formed using a BD Cytoﬁx/Cytoperm kit (BD Biosciences).
Samples were acquired on a FACSCanto II instrument using
FACSDiva software version 6.1.2 (BD Biosciences), and ﬂow
cytometric data were analyzed using FlowJo software version
8.8.6 (TreeStar, Ashland, OR). Fluorescence 1 controls were
used to ensure speciﬁcity in data analysis; doublets were
excluded by forward- and side-scatter proﬁle.
For CD4þ T cell transfer studies, CD4þ T cells were
isolated from spleens of WT or Il17a/ mice by magnetic-
activated cell sorting using L3T4 MicroBead antibody
(Miltenyi Biotec), as described previously.16 CD4þ T cell
purity, assessed by ﬂow cytometric analysis, was similar for
WT and Il17a/ mice (94.9% versus 94.8%, respectively).
Analysis was performed on a Mo-Flo cytometer (Dako
Australia, Botany, Australia). We injected 3  106 CD4þ
T cells (from WT or Il17a/ mice) intravenously intoThe American Journal of Pathology - ajp.amjpathol.orgRag1/ mice and waited 3 weeks to facilitate reconstitu-
tion, according to published protocols.11
Statistical Analysis
Student’s t-test was used for analysis of two groups and one-
way analysis of variance (Tukey’s post hoc test) for more
than two groups of data using GraphPad Prism software
version 6.0 (GraphPad Software, San Diego, CA). P < 0.05
was considered signiﬁcant.Results
Kidney IL-17A Expression Is Increased after
Cisplatin-Induced Injury
We have previously shown that, after cisplatin administra-
tion, renal inﬂammation peaks after 24 hours and substantial
kidney injury has occurred by 96 hours.18 We therefore
injected WT mice with cisplatin and measured kidney
expression of IL-17A and related chemokines at 24 and
96 hours after injection. Kidney mRNA for IL-17A peaked
at 24 hours and had returned to baseline levels by 96 hours
(Figure 1A). CCL20, an important chemokine in CD4þ1413
Figure 3 Mice deﬁcient in the key IL-17A transcription factor RORgt
are protected from cisplatin-induced renal injury. A and B: Compared with
cisplatin-injected WT mice, functional (A) and histological (B) renal injury
was decreased in cisplatin-injected Rorgt/ mice. C and D: Representative
photomicrographs of renal injury in WT (C) and Rorgt/ (D) mice. Data are
expressed as means  SEM. n Z 7 (WT); n Z 9 (Rorgt/). *P < 0.05;
**P < 0.01. Original magniﬁcation, 100.
Figure 4 Pre-emptive treatment with antieIL-17A antibody decreases
cisplatin-induced renal injury. A and B: WT mice were treated with antieIL-
17A antibodies or an isotype control antibody before cisplatin injections
and every other day for the duration of the experiment. Functional (A) and
histological (B) renal injury was decreased after administration of antieIL-
17A therapy. C and D: Representative photomicrographs of renal injury in
WT mice treated with isotype control (C) and antieIL-17A (D) antibodies.
Data are expressed as means  SEM. *P < 0.05, ***P < 0.001. nZ 7 per
group. Original magniﬁcation, 100.
Chan et alTh17 cell recruitment, peaked at 96 hours after cisplatin-
induced injury (Figure 1B). Of two key neutrophil chemo-
attractants, CXCL1 peaked at 24 hours, whereas CXCL2
was higher at 96 hours (Figure 1, C and D).
Endogenous IL-17A and RORgt Mediate Functional and
Histological Renal Injury
WTand Il17a/micewere administered cisplatin, and kidney
injury was assessed 96 hours later. BUN and histological renal
injury were diminished in the absence of IL-17A (Figure 2, A
and B). The marked tubular necrosis and injury consistently
observed in WT mice after cisplatin administration was
reduced in the absence of endogenous IL-17A (Figure 2, C and
F). Todeﬁne the role ofRORgt, the key transcription factor that
induces IL-17A, we injected WT and Rorgt/ mice with
cisplatin and assessed renal injury 96 hours later. Compared
with WT mice, there was a decrease in functional and histo-
logical renal injury in Rorgt/ mice (Figure 3).
To assess the potential of IL-17A inhibition in AKI, we
administered antieIL-17A antibodies (or isotype control
antibodies) to WT mice 1 day before cisplatin-induced
injury, with further doses 1 and 3 days after cisplatin. Mice
treated with antieIL-17A antibodies showed less functional
and histological renal injury after 96 hours (Figure 4).
TLR2 Activation and the ASC-Dependent
Inﬂammasome Complex Regulate Kidney IL-17A
Production and Injury
Because both the inﬂammasomes and TLR2 have been
implicated in IL-17A production, we administered cisplatin1414to WT, Asc/, and Tlr2/mice. After 96 hours, one kidney
was homogenized and the supernatants were assessed by
enzyme-linked immunosorbent assay for IL-17A and IL-1b
production. Compared with WT mice, production of kidney
IL-17A and IL-1b was decreased in both Asc/ and Tlr2/
mice (Figure 5, A and B). Renal injury was decreased in both
Asc/ and Tlr2/ mice (Figure 5, CeG), indicating that
TLR2 binding and ASC activation are required both for
production of IL-17A within the kidney and for development
of injury.
Both Neutrophils and CD4þ T Cells Produce IL-17A, and
Neutrophil Recruitment Is IL-17A Dependent
Subsequently, we injected WT mice with cisplatin and
assessed IL-17A production by intrarenal leukocytes
(Figure 6, AeC). Both innate (Ly6Gþ neutrophils) and
adaptive (CD4þ T cells) immune cells produced IL-17A;
approximately 30% of the IL-17Aeproducing cells were
neutrophils and 15% were CD4þ T cells. Compared with
cisplatin-injected WT mice, neutrophil recruitment in Il17a/
mice was diminished in the absence of IL-17A at 24 hours
(Figure 6, DeF), but interstitial CD4þ T-cell recruitment
was unchanged (Figure 6, GeI). IL-17A deﬁciency did not
result in signiﬁcant changes to intrarenal expression of
CXCL1, CXCL2, CCL2, or CCL5 mRNA 24 hours after
cisplatin (Table 1). Thus, although both neutrophils and
CD4þ T cells in the injured kidney produce IL-17A, only
neutrophil recruitment requires endogenous cisplatin-induced
IL-17A production.ajp.amjpathol.org - The American Journal of Pathology
Figure 5 ASC inﬂammasome activation and TLR2 binding is required for
the production of renal IL-17A and cisplatin-induced renal injury. AeG:
WT, Asc/, and Tlr2/ mice were injected with cisplatin, and kidney
homogenates were assessed for cytokine production. A and B: Kidney IL-
17A (A) and IL-1b (B) production decreased in Asc/ and Tlr2/ mice.
C and D: Functional (C) and histological (D) injury was also decreased in
Asc/ and Tlr2/ mice injected with cisplatin. EeG: Representative
photomicrographs of renal injury in WT (E), Asc/ (F), and Tlr2/ (G)
mice. Data are expressed as means  SEM. n Z 5 (Asc/ and Tlr2/);
nZ 10 (WT). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001
versus WT. Original magniﬁcation, 100.
IL-17A Directs Acute Kidney InjuryCisplatin-Induced AKI Occurs Independently of gd T
Cells and of IL-17A Produced by T Cells
To determine whether gd T cells are required for AKI, we
administeredcisplatin toWTandTcrd/mice (which lackgdT
cells). There was no difference in functional and histological
renal injury between WT and Tcrd/ mice after 96 hours
(Figure 7, A and B). T cells are important mediators of renal
injury after cisplatin administration,11 and Rag1-deﬁcient mice
lack adaptive immune cells. We reconstituted the T-cell
compartment of Rag1/ mice with CD4þ T cells fromWT or
Il17a/mice and then injected theRag1/micewith cisplatin.
WT CD4þ T cells enhanced renal injury, compared with
cisplatin-injected unreconstituted Rag1/ mice; reconstitution
with Il17a-deﬁcient T cells resulted in similar increases in
functional and histological injury (Figure 7, C and D).
Innate Effector Cells Propagate IL-17AeInduced AKI
To investigate whether the effects of IL-17A inhibition result
solely from decreased renal neutrophil recruitment, we
treated three groups of WT mice with cisplatin. The ﬁrst
group received isotype control antibodies alone, the second
group underwent neutrophil depletion using an anti-Ly6GThe American Journal of Pathology - ajp.amjpathol.organtibody with an additional isotype control antibody, and the
third group underwent neutrophil depletion (anti-Ly6G
antibodies) and IL-17A inhibition using an antieIL-17A
antibody. Although there was a decline in functional and
histological injury in mice treated with anti-Ly6G antibody,
this reached statistical signiﬁcance only after the additional
administration of an antieIL-17A antibody (Figure 8, A andB).
These results indicate that the effects of IL-17A inhibition
extend beyond limiting the pathogenic effects of neutrophils.
Because NK cells also can produce IL-17A, we investi-
gated their contribution to cisplatin-induced AKI using three
groups of cisplatin-injected mice. The ﬁrst group received
control antibodies, the second group underwent depletion of
NK cells and neutrophils (receiving both anti-NK1.1 and
anti-Ly6G antibodies), and the third group, in addition to
being depleted of NK cells and neutrophils, also underwent
IL-17A inhibition. Although functional and histological
renal injury diminished after treatment with anti-NK1.1 and
anti-Ly6G, the addition of antieIL-17A therapy did not
offer additional therapeutic protection (Figure 8, C and D).
These results indicate that innate immune cells are the key
drivers of IL-17Aemediated AKI.
Discussion
In our present studies, we demonstrated that innate IL-17A
is a signiﬁcant contributor to cisplatin-induced AKI.
Neutralizing endogenous IL-17A signiﬁcantly attenuated
renal functional and histological damage, thus identifying
antieIL-17Aebased therapies as potential treatments for
human drug-induced AKI. Activation of TLR2 and the ASC
inﬂammasome were required for generation of IL-17A
within the kidney. The injurious effects of IL-17A resulted
from recruitment of innate effector cells, rather than to
IL-17A produced from CD4þ T cells or gd T cells.
The demonstration of the important role for IL-17A in
cisplatin-induced AKI has clinical implications. Several IL-
17A neutralizing antibodies tested in clinical practice show
great promise for treating psoriasis, psoriatic arthritis, and
ankylosing spondylitis.7 IL-17A serum levels are increased
in patients with glomerulonephritis and correlate with dis-
ease severity in patients with autoimmune anti-neutrophil
cytoplasmic antibodyeassociated vasculitis23 and lupus
nephritis.24 However, antieIL-17A monoclonal antibodies
have not yet been tested in the treatment of kidney diseases.
Given that pre-emptive treatment with antieIL-17A anti-
body protected mice from cisplatin-induced AKI, this ther-
apy may be useful in clinical AKI. The occurrence of AKI is
often predictable, so preventive treatment with antieIL-17A
therapy could improve clinical outcomes.
Innate pattern recognition receptors, including TLRs and
the inﬂammasome, trigger inﬂammation in response to both
invading pathogens and endogenous molecules released from
injured tissue.25,26 Activation of the inﬂammasome results in
the production of active IL-1b and IL-18, important media-
tors of inﬂammation whose production and release is tightly1415
Figure 6 Interstitial neutrophil recruitment is
reduced in the absence of IL-17A. AeC: Repre-
sentative ﬂow cytometry plots for IL-17Ae
secreting cells in kidney from WT mice injected
with cisplatin (AeC). IL-17A is produced by CD45þ
leukocytes (A). Of cells that produce IL-17A, a
signiﬁcant proportion are Ly6Gþ neutrophils (B),
but some CD4þ T cells also produce IL-17A (C).
DeI: At 24 hours after cisplatin-induced injury,
interstitial neutrophil recruitment decreased in
Il17a/ mice, compared with WT mice (D).
Representative photomicrographs show the differ-
ence in recruitment of neutrophils (arrows) in WT
(E) and Il17a/ (F) mice. Recruitment of inter-
stitial CD4þ T cells (arrows in H and I) did not differ
between genotypes (G), as seen also in represen-
tative photomicrographs from WT (H) and Il17a/
(I) mice. Data are expressed as means SEM. nZ 9
(Il17a/); n Z 10 (WT). ***P < 0.001. Original
magniﬁcation, 200. hpf, high-power ﬁeld.
Chan et alcontrolled. Before activation of the inﬂammasome, an
initiating signal provided by TLR binding is required,
resulting in the generation of proeIL-1b and proeIL-18
(often referred to as signal 1). Subsequent activation of the
inﬂammasome results in the generation of active IL-1b and
IL-18, which then induces the downstream generation of
IL-17A.9 In the present study, intrarenal IL-17A production
was diminished in Asc/ mice, which were also protected
from renal injury. Similarly, Tlr2/ mice demonstrated
decreased renal IL-1b and IL-17A production, with renal
protection. These results suggest that ﬁndings reported in
models of infection are also relevant in inﬂammatory renal
disease.8,9
It is likely that, when cisplatin administration triggers cell
necrosis, endogenous TLR2 ligands are produced that bind
TLR2.27,28 The resultant ASC-dependent inﬂammasome
activation leads to the IL-17A production that mediates
injury. The adaptor protein ASC is involved in two
inﬂammasome complexes, the NLRP3 and AIM2,26 andTable 1 Intrarenal Chemokine mRNA Expression at 24 Hours
after Cisplatin-Induced Renal Injury in WT and Il17a/ Mice
Kidney mRNA WT (RQ) Il17a/ (RQ)
CXCL1 1.0  0.4 1.9  0.6
CXCL2 1.0  0.2 0.9  0.2
CCL2 1.0  0.1 1.4  0.4
CCL5 1.0  0.1 1.0  0.1
Data are expressed as means  SEM. n Z 10 (WT); n Z 9 (Il17a/).
P > 0.05.
RQ, relative quantiﬁcation.
1416further studies are needed to determine the relative contri-
bution of each complex in this process. Although we have
identiﬁed IL-17A as a potential therapeutic target, our
ﬁndings also help identify additional upstream targets.
The role of CD4þ T cells producing IL-17A in autoim-
mune and inﬂammatory renal disease has been well studied.
In a planted antigen model of glomerulonephritis, Th17 cells
induce proliferative glomerulonephritis by recruiting neu-
trophils to glomeruli.29 Similarly pathogenic roles for IL-
17A have been demonstrated in CD4þ T-celledependent
models of rapidly progressive glomerulonephritis.15,30
CD4þ T cells play a role in cisplatin-induced renal injury;
CD4þ T celledeﬁcient mice are protected from cisplatin-
induced AKI, whereas reconstitution with CD4þ T cells
restores injury.11 In a previous study, Rag1/ mice were
protected from injury after cisplatin administration.20
Reconstitution of the CD4þ T cell compartment before
cisplatin injections restored the pattern and intensity of
injury. However, although kidney expression of the key
Th17 chemokine CCL20 increased after cisplatin adminis-
tration, the accumulation of interstitial CD4þ T cells was not
altered in the absence of IL-17A. Furthermore, reconstitut-
ing Rag1/ with Il17a-deﬁcient CD4þ T cells resulted in
injury similar to that seen when WT CD4þ T cells were
used. The results conﬁrm that IL-17A produced by CD4þ T
cells is not important in cisplatin-induced AKI. Recently, gd
T cells have been identiﬁed as important in several IL-17Ae
mediated diseases,31 including glomerulonephritis induced
by a planted foreign antigen.32 Because Tcrd/ mice
develop less injury after undergoing ischemic AKI,13 weajp.amjpathol.org - The American Journal of Pathology
Figure 8 Inhibition of both neutrophils and NK cells protects WT
mice from cisplatin-induced renal injury. A and B: WT mice treated
with control antibodies and cisplatin developed signiﬁcant functional
(A) and histological (B) renal injury. Pre-emptive neutrophil depletion
with anti-Ly6G, followed by cisplatin, resulted in a trend toward
attenuated injury; however, a combination of neutrophil depletion and
antieIL-17A neutralization before cisplatin injections signiﬁcantly
attenuated renal injury. C and D: WT mice treated with control antibodies
and cisplatin developed signiﬁcant functional (C) and histological (D)
renal injury. Pre-emptive treatment of WT mice with anti-Ly6G and anti-
NK1.1 antibodies offered signiﬁcant protection, which was not
enhanced after additional IL-17A neutralization. Data are expressed as
means SEM. nZ 6 (A and B, white and gray bars); nZ 7 (A and B, solid
bars; C and D). *P < 0.05, **P < 0.01, and ***P < 0.001.
Figure 7 Cisplatin-induced renal injury is not mediated by gd T cells or
CD4þ T cells that produce IL-17A. A and B: Compared with renal injury
observed in WT mice injected with cisplatin, functional (A) and histological
(B) injury did not differ in Tcrd/ mice, which lack gd T cells. C and D:
Subsequently, we reconstituted Rag1/ mice with CD4þ T cells; when
reconstitution was complete, mice were administered cisplatin. Although
renal injury was increased in Rag1/ mice reconstituted with WT CD4þ
T cells compared with unreconstituted Rag1/ (dashed lines), functional
(C) and histological (D) injury in Rag1/ mice reconstituted with Il17a-
deﬁcient CD4þ T cells was similar to that seen when WT cells were used. Data
are expressed as means SEM. nZ 8 (WT, A and B); nZ 9 (Tcrd/); nZ 7
[Rag1/ unreconstituted (dashed lines); Rag1/mice receiving Il17a/
CD4þ T cells; and Rag1/ mice receiving WT CD4þ T cells].
IL-17A Directs Acute Kidney Injurypostulated that gd T cells contribute to cisplatin-induced
AKI. However, deleting gd T cells did not alter functional
and histological renal injury.
The inﬂammatory effects of IL-17A are exerted not only
through adaptive immune cells, but also through innate
immune cells (neutrophils, in particular). In response to
microbial infection, IL-17A produced within 4 hours en-
hances the production of neutrophil-attracting chemokines,
thus stimulating neutrophil recruitment.33 Although early
IL-17Aeinduced neutrophil recruitment is important in host
defense after bacterial and fungal infections,31 IL-17Ae
directed neutrophil recruitment can be injurious.12,34 After
cisplatin injections, fewer neutrophils were seen in kidneys
of Il17a/ mice, compared with WT mice, although
changes in CXCL1 and CXCL2 expression were unclear.
These results indicate that IL-17A is required for neutrophil
recruitment after cisplatin administration.
Pre-emptive neutrophil depletion with anti-Ly6G anti-
body partially attenuated renal injury, although this did not
reach statistical signiﬁcance unless IL-17A was also
inhibited, suggesting that the action of IL-17A inhibition
extends beyond prevention of neutrophil recruitment. Data
on the role of neutrophils in cisplatin-induced renal injury
are somewhat conﬂicting. It has been shown that interstitial
neutrophil recruitment increases after cisplatin administra-
tion, although administration of a single dose of antieGr-1
antibody did not attenuate renal injury.35 However, Cxcr2-
deﬁcient mice, which lack the receptor for CXCL1 andThe American Journal of Pathology - ajp.amjpathol.orgCXCL2, were protected from cisplatin-induced AKI.36
Thus, it would seem likely that effective neutrophil deple-
tion offers some protection (although not complete protec-
tion) from cisplatin-induced AKI and that this effect is, at
least partially, IL-17A dependent.
We also found that the renal protection observed after
depletion of neutrophils and NK1.1 cells was not further
enhanced after IL-17Aneutralization. In kidney biopsies from
humanswith acute tubular necrosis, NK1.1þ cells form part of
the inﬂammatory milieu,37 and NK1.1þ cells drive kidney
injury after ischemiaereperfusion.14 In cisplatin-induced
AKI, numbers of NK1.1þ cells increased with disease pro-
gression, although inhibition did not signiﬁcantly attenuate
renal injury.38 These results, together with our present
ﬁndings, suggest that inhibiting neutrophils or NK1.1þ cells
alone is insufﬁcient to protect from cisplatin-induced AKI;
however, inhibition of both neutrophils and NK1.1þ cells
offers protection, which is most likely mediated through
IL-17A.
In conclusion, IL-17A mediates cisplatin-induced AKI,
and IL-17A blockade has therapeutic promise. Activation of
TLR2 and the ASC-dependent inﬂammasome complex is
required for generation of renal IL-17A and renal injury.1417
Chan et alThe mechanism of IL-17Aeinduced injury involves a
combination of innate effector cells, rather than IL-17Ae
producing CD4þ T cells or gd T cells.References
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